Connect your AI

BridgeBio Pharma BBIO Investment Purchases

Investment Purchases at other companies

Ionis PharmaceuticalsIONS

$192.76M-38.0%

BioMarin PharmaceuticalsBMRN

$25.79M-71.1%

Arrowhead ResearchARWR

$924.64M+43.5%

Neurocrine BiosciencesNBIX

$819.5M+200%

BiogenBIIB

$748.8M—

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's investment purchases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BridgeBio Pharma's investment purchases?: BridgeBio Pharma (BBIO) reported investment purchases of $52.67M in Q1 2026.
What does investment purchases mean?: Cash spent to acquire financial investments or marketable securities.
How do you interpret investment purchases?: High outflows indicate a focus on capital preservation and yield generation for idle cash balances.
How does investment purchases compare across companies?: Standard for companies with significant cash reserves; peers often hold high-quality liquid assets.